Your browser doesn't support javascript.
loading
Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders.
Oertel, Frederike Cosima; Zimmermann, Hanna G; Motamedi, Seyedamirhosein; Chien, Claudia; Aktas, Orhan; Albrecht, Philipp; Ringelstein, Marius; Dcunha, Anitha; Pandit, Lekha; Martinez-Lapiscina, Elena H; Sanchez-Dalmau, Bernardo; Villoslada, Pablo; Palace, Jacqueline; Roca-Fernández, Adriana; Leite, Maria Isabel; Sharma, Srilakshmi M; Leocani, Letizia; Pisa, Marco; Radaelli, Marta; Lana-Peixoto, Marco Aurélio; Fontenelle, Mariana Andrade; Havla, Joachim; Ashtari, Fereshteh; Kafieh, Rahele; Dehghani, Alireza; Pourazizi, Mohsen; Marignier, Romain; Cobo-Calvo, Alvaro; Asgari, Nasrin; Jacob, Anu; Huda, Saif; Mao-Draayer, Yang; Green, Ari J; Kenney, Rachel; Yeaman, Michael R; Smith, Terry J; Cook, Lawrence; Brandt, Alexander U; Paul, Friedemann; Petzold, Axel.
Afiliação
  • Oertel FC; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Zimmermann HG; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Motamedi S; Department of Neurology, University of California San Francisco, San Francisco, California, USA.
  • Chien C; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Aktas O; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Albrecht P; Einstein Center Digital Future, Berlin, Germany.
  • Ringelstein M; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Dcunha A; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Pandit L; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Martinez-Lapiscina EH; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Sanchez-Dalmau B; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Villoslada P; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Palace J; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Roca-Fernández A; Centre for Neurology and Neuropsychiatry, Landschaftsverband Rheinland-Klinikum Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Leite MI; Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India.
  • Sharma SM; Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India.
  • Leocani L; Hospital Clinic of Barcelona-Institut d'Investigacions, Biomèdiques August Pi Sunyer, (IDIBAPS), Barcelona, Spain.
  • Pisa M; Hospital Clinic of Barcelona-Institut d'Investigacions, Biomèdiques August Pi Sunyer, (IDIBAPS), Barcelona, Spain.
  • Radaelli M; Hospital Clinic of Barcelona-Institut d'Investigacions, Biomèdiques August Pi Sunyer, (IDIBAPS), Barcelona, Spain.
  • Lana-Peixoto MA; Wu Tsai Neurosciences Institute, Stanford University, Palo Alto, California, USA.
  • Fontenelle MA; Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.
  • Havla J; Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.
  • Ashtari F; Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.
  • Kafieh R; Department of Ophthalmology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.
  • Dehghani A; Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE) Scientific Institute San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
  • Pourazizi M; Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE) Scientific Institute San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
  • Marignier R; Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE) Scientific Institute San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
  • Cobo-Calvo A; CIEM MS Research Center, University of Minas Gerais, Medical School, Belo Horizonte, Brazil.
  • Asgari N; CIEM MS Research Center, University of Minas Gerais, Medical School, Belo Horizonte, Brazil.
  • Jacob A; Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians Universität München, Munich, Germany.
  • Huda S; Kashani MS Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Mao-Draayer Y; School of advanced technologies in medicine and Medical Image and Signal processing Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Green AJ; Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Kenney R; Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Yeaman MR; Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
  • Smith TJ; Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
  • Cook L; Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Brandt AU; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Paul F; Departments of Neurology, Slagelse Hospitals Denmark, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Petzold A; Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
J Neurol Neurosurg Psychiatry ; 94(7): 560-566, 2023 07.
Article em En | MEDLINE | ID: mdl-36810323
ABSTRACT

BACKGROUND:

The novel optic neuritis (ON) diagnostic criteria include intereye differences (IED) of optical coherence tomography (OCT) parameters. IED has proven valuable for ON diagnosis in multiple sclerosis but has not been evaluated in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4+NMOSD). We evaluated the diagnostic accuracy of intereye absolute (IEAD) and percentage difference (IEPD) in AQP4+NMOSD after unilateral ON >6 months before OCT as compared with healthy controls (HC).

METHODS:

Twenty-eight AQP4+NMOSD after unilateral ON (NMOSD-ON), 62 HC and 45 AQP4+NMOSD without ON history (NMOSD-NON) were recruited by 13 centres as part of the international Collaborative Retrospective Study on retinal OCT in Neuromyelitis Optica study. Mean thickness of peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell and inner plexiform layer (GCIPL) were quantified by Spectralis spectral domain OCT. Threshold values of the ON diagnostic criteria (pRNFL IEAD 5 µm, IEPD 5%; GCIPL IEAD 4 µm, IEPD 4%) were evaluated using receiver operating characteristics and area under the curve (AUC) metrics.

RESULTS:

The discriminative power was high for NMOSD-ON versus HC for IEAD (pRNFL AUC 0.95, specificity 82%, sensitivity 86%; GCIPL AUC 0.93, specificity 98%, sensitivity 75%) and IEPD (pRNFL AUC 0.96, specificity 87%, sensitivity 89%; GCIPL AUC 0.94, specificity 96%, sensitivity 82%). The discriminative power was high/moderate for NMOSD-ON versus NMOSD-NON for IEAD (pRNFL AUC 0.92, specificity 77%, sensitivity 86%; GCIP AUC 0.87, specificity 85%, sensitivity 75%) and for IEPD (pRNFL AUC 0.94, specificity 82%, sensitivity 89%; GCIP AUC 0.88, specificity 82%, sensitivity 82%).

CONCLUSIONS:

Results support the validation of the IED metrics as OCT parameters of the novel diagnostic ON criteria in AQP4+NMOSD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurite Óptica / Neuromielite Óptica / Aquaporinas Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurite Óptica / Neuromielite Óptica / Aquaporinas Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article